RxDoctor Payments DataLook up a doctor →

Malcolm Roland, MD

Neurology · Oxford, MSNPI 1033325022

Payments from drug & device makers

$26,268in general payments, 2019–2025

Across 1,552 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$2K
  • Biogen$1K
  • Amgen$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • plus $17K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)211$2,845
Novartis122$1,821
Biogen69$1,203
Amgen(2 entities)79$1,169
Pfizer75$1,162
Lilly USA, LLC64$1,089
Acadia Pharmaceuticals Inc66$1,054
Jazz Pharmaceuticals Inc.50$1,027
UCB, Inc.42$900
EMD Serono, Inc.50$863
AstraZeneca(2 entities)41$843
SK Life Science, Inc.36$827
Harmony Biosciences LLC33$741
Neurocrine Biosciences, Inc.48$719
Teva Pharmaceuticals USA, Inc.45$707
Amneal Pharmaceuticals LLC45$661
Bristol Myers Squibb32$637
Lundbeck LLC33$621
Genentech USA, Inc.32$556
Sanofi27$527
Eisai Inc.28$525
Tanabe Pharma America, Inc.28$446
Acorda Therapeutics, Inc20$411
Biohaven Pharmaceutical Holding Company Ltd.25$392
Argenx US, Inc.16$358
Avanir Pharmaceuticals, Inc.24$349
Supernus Pharmaceuticals, Inc.21$341
Johnson & Johnson(2 entities)26$338
Sunovion Pharmaceuticals Inc.26$336
Inspire Medical Systems, Inc.7$306
Biohaven Pharmaceuticals, Inc.18$252
Neurelis, Inc.11$218
Kyowa Kirin, Inc.12$213
Merz Pharmaceuticals, LLC5$143
Otsuka America Pharmaceutical, Inc.7$142
Catalyst Pharmaceuticals, Inc.6$129
Greenwich Biosciences, Inc.7$127
Corium, LLC8$118
Springworks Therapeutics, Inc.4$108
Mallinckrodt Enterprises LLC5$89
TG Therapeutics, Inc.4$82
Upsher-smith Laboratories LLC4$75
Kedrion Biopharma, Inc.1$73
CSL Behring3$65
ANI Pharmaceuticals, Inc.3$59
Vanda Pharmaceuticals Inc.2$56
Boston Scientific2$51
Mallinckrodt Hospital Products Inc.2$42
Nevro Corp.2$40
Alnylam Pharmaceuticals Inc.2$39
Merz North America, Inc.2$36
GRT US Holding, Inc.3$36
GE HealthCare2$35
Fisher & Paykel Healthcare Inc2$33
Medtronic(2 entities)2$33
Assertio Therapeutics, Inc.2$24
Averitas Pharma Inc.1$24
Cala Health, Inc.1$22
Sanofi-aventis U.S. LLC1$20
Piramal Critical Care1$19

How this compares

$26,268 in reported general payments places this provider in the 80th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$311,153
Medicare patients
761
Services billed
20,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →